|
Indications and Dosage
Oral
Pain relief Adult: 8-16 mg daily. Max: 24 mg daily. Oral Osteoarthritis, Rheumatoid arthritis Adult: 12 mg daily in 2-3 divided doses, up to 16 mg daily if needed. Parenteral Pain relief Adult: 8 mg once or twice daily by IM/IV inj. Max: 24 mg daily.
|
|
Contraindications
Patients with peptic ulceration; severe renal impairment; pregnancy and lactation.
|
|
Special Precautions
Active infections; asthma; allergic disorders; haemorrhagic disorders; hypertension; impaired renal, hepatic, cardiac function.
|
|
Adverse Reactions
Abdominal pain, diarrhoea, dizziness, dyspepsia, nausea, vomiting; headache; haematologic disorders; CNS effects; visual disturbance; tinnitus; nephrotoxicity; fluid retention; photosensitivity; alveolitis; pancreatitis; Stevens-Johnson syndrome; toxic epidermal necrolysis; colitis induction/exacerbation; stomatitis; hypertension, palpitation; insomnia, somnolence.
|
|
Drug Interactions
Increased lornoxicam blood conc when given concomitantly with cimetidine.Enhanced effects of anticoagulants, sulfonylureas, methotrexate, ciclosporin, digoxin. Decreased effects of diuretics, ACE inhibitors.
Potentially Fatal: Increased risk of lithium toxicity. |
|
Action
Description:
Mechanism of Action: Lornoxicam is an NSAID that is used in musculoskeletal, joint disorders and other painful conditions including postoperative pain. Lornoxicam is a potent inhibitor of both COX-1 and COX-2 enzymes. Pharmacokinetics: Absorption: Extensively absorbed from the GI tract. Peak plasma concentration within 1-2 hr (oral) or 25 min (IM). Distribution: 99% bound to plasma proteins. Metabolism: Metabolised to its inactive metabolite. Excretion: Excreted in the faeces (as metabolites) and urine (as unchanged drug). Mean elimination half life of 3-4 hr. |
Sign Out
